R&D Insight

(Re)using surveillance data: 2024 Vivli Challenge Awardees

Dear All, I’ve written before about the Vivli AMR Surveillance Data Challenge that seeks creative ways to reuse MICs from surveillance datasets (the 24 April 2023 newsletter covered the 2023 Challenge; the 15 June 2024 newsletter flagged the 2024 Challenge).  As a reminder, Vivli is a clinical data sharing platform that was created in 2013 from a

Read More »

NIAID/DMID call for antibacterials, antifungals, vaccines, & diagnostics

Dear All, Just released, the 2026 NIAID DMID Omnibus Broad Agency Announcement (HHS-NIH-NIAID-BAA2025-1) seeks applications for projects to treat, prevent, and diagnose bacterial, fungal, and viral infections. Of interest for this community, the BAA’s Research Area 001 seeks applications by 21 Feb 2025 for bacterial and fungal projects across thee topics (see below my signature for

Read More »

Conflict-Borne XDR Superbugs: It’s Time for the PASTEUR Act!

Dear All: The recent publication of an exceptionally good plain-language summary of the AMR problem in Rolling Stone (yes, you read that correctly!) prompts today’s 3-part journey into the way(s) that war contributes to the threat of resistant superbugs. We’ve summarized the story in outline form — please explore the references for further details. And

Read More »

Environmental, Animal, and Human Uses of Phage: WHO webinars

Dear All, I have just this weekend learned of a 3-part WHO webinar series on uses of phage. Two of the webinars have already been held; the 3rd is scheduled for 16 May. All are / will be available for post-webinar review. The links you need are below — in addition, a copy of the

Read More »

NIAID RFA: Centers for Accelerating Phage Therapy (CAPT-CEP)

Dear All, I was delighted to learn today that NIAID has released RFA-AI-24-069, a notice of funding opportunity (NOFO) soliciting applications to establish Centers for Accelerating Phage Therapy to Combat ESKAPE Pathogens (CAPT-CEP). The CAPT-CEPs will focus on developing preclinical assays, tools, and models for robust phage therapy R&D and advancing phage clinical research. Applications are due

Read More »

WHO Antibacterial Pipeline Review: Update thru 31 Dec 2023

Dear All, WHO have released an update through 31 Dec 2023 of their ongoing series of antibacterial pipeline reviews! Here are the links you need: The report: 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis and a press release about the report. Infographics: Key facts and recommendations from the 2023 antibacterial agents in clinical

Read More »

Vivli: Access to Industry’s Susceptibility Surveillance data

Dear All (and with thanks to Patricia Bradford for leading on this newsletter), Did you know you can access raw datasets of antimicrobial susceptibility surveillance data that have been generated by the pharmaceutical industry? Indeed such datasets exist and we’d like to ensure everyone is aware of their availability and potential! Background: The 20 Oct

Read More »

WHO: AMR Policy Brief and Preclinical pipeline data call

Dear All, Supplementing and augmenting their review of the clinical and preclinical pipeline through 31 Dec 2023 (see the 15 June 2024 newsletter for details), WHO have now released: A call for data on preclinical antibacterial projects Scope: Traditional and non-traditional antibacterial candidates covering the WHO bacterial priority pathogens as well as other resistant pathogens of public health

Read More »

All-in cost of a new antibiotic from discovery to 10 years on market

Dear All (and with thanks to Kevin Krause for co-authoring this newsletter), The elements that contribute to the all-in cost of an antibiotic have been reviewed in two prior newsletters: 6 Mar 2020 (focused on cost of R&D to approval): What does an antibiotic cost to develop? What is it worth? How to afford it? 7 Jan

Read More »
Scroll to Top